Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 45, 2021 - Issue 2
1,547
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry

, , , , , & show all
Pages 80-86 | Received 11 Nov 2020, Accepted 25 Feb 2021, Published online: 13 May 2021

References

  • Gardner RV. Sickle cell disease: advances in treatment. Ochsner J. 2018;18(4):377–389.
  • Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573.
  • Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–487.
  • Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858–863.
  • Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician. 2000;61(5):1349–1356, 1363–1364. Erratum: Am Fam Physician. 2001;64(2):220.
  • Powars DR. Natural history of sickle cell disease–the first ten years. Semin Hematol. 1975;12(3):267–285.
  • Alexander N, Higgs D, Dover G, et al. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol. 2004;126(4):606–611.
  • Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94–101.
  • Khoriaty E, Halaby R, Berro M, et al. Incidence of sickle cell disease and other hemoglobin variants in 10,095 Lebanese neonates. PLoS One. 2014;9(9):e105109.
  • Inati A, Jradi O, Tarabay H, et al. Sickle cell disease: the Lebanese experience. Int J Lab Haematol. 2007;29(6):399–408.
  • McGann PT. Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality. J Pediatr. 2014;165(1):18–22.
  • Piel FB. The present and future global burden of the inherited disorders of hemoglobin. Hematol Oncol Clin North Am. 2016;30(2):327–341.
  • American Society of Hematology (ASH): State of Sickle Cell Disease 2016 Report. [pdf] Available from http://www.scdcoalition.org/pdfs/ASH State of Sickle Cell Disease 2016 [accessed June 6 2019].
  • Centers for Disease Control and Prevention. Data & Statistics on Sickle Cell Disease. https://www.cdc.gov/ncbddd/sicklecell/data.html [accessed November 11 2019].
  • Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892–3898.
  • Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–327.
  • Dong H, Robison LL, Leisenring WM, et al. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181(7):532–540.
  • Badawy SM, Thompson AA, Holl JL, et al. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018;35(5–6):297–308.
  • Badawy SM, Thompson AA, Lai J-S, et al. Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017;15(1):136.
  • Elion J, Berg PE, Lapouméroulie C, et al. DNA sequence variation in a negative control region 5′ to the beta-globin gene correlates with the phenotypic expression of the beta s mutation. Blood. 1992;79(3):787–792.
  • Jeffreys AJ. DNA sequence variants in the G gamma-, A gamma-, delta- and beta-globin genes of man. Cell. 1979;18(1):1–10.
  • Kulozik AE, Wainscoat JS, Serjeant GR, et al. Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet. 1986;39(2):239–244.
  • Inati A, Taher A, Bou Alawi W, et al. Beta-globin gene cluster haplotypes and Hb F levels are not the only modulators of sickle cell disease in Lebanon. Eur J Haematol. 2003;70(2):79–83.
  • Bronté-Hall L, Parkin M, Green C, et al. Real-world clinical burden of sickle cell disease in the US community-practice setting: a single-center experience from the Foundation for Sickle Cell Disease Research [abstract]. Blood. 2019;134(1):5856.
  • Brousse V, Arnaud C, Lesprit E, et al. Evaluation of outcomes and quality of care in children with sickle cell disease diagnosed by newborn screening: a real-world nation-wide study in France. J Clin Med. 2019;8(10):1594.
  • Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625–635.
  • Heeney MM, Abboud MR, Amilon C, et al. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019;85:105835.